#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Infiltration of Prostate Cancer by CD204+ and CD3+ Cells Correlates with ERG Expression and TMPRSS2-ERG Gene Fusion


Authors: A. Burdova 1,2;  P. Rulisek 1;  J. Bouchal 1;  M. Král 1;  V. Student 1;  Z. Kolar 1
Authors‘ workplace: Medicine, Faculty of Medicine, Palacky University and University Hospital, Olomouc ;  Department of Clinical and Molecular Pathology and Institute of Molecular and Translational 1;  Department of Medical Genetics, AGEL Laboratories, Nový Jičín 2
Published in: Klin Onkol 2018; 31(6): 421-428
Category: Original Articles
doi: https://doi.org/10.14735/amko2018421

Overview

Background:

The aim of the study was to detect CD204 + and CD3 + cells in the infiltrate of benign prostatic hyperplasia, prostatic intraepithelial neoplasia and prostatic cancer in prostate specimens after radical prostatectomy. Another goal was to determine correlation of the intensity of the infiltration with ERG oncoprotein expression as well as with the presence of activat­ing translocation TMPRSS2-ERG.

Materials and Methods: To confirm the translocation, we used fluorescence in situ hybridization. Imunohistochemistry was used to detect the presence of ERG oncoprotein and for assesment of the number of CD204+ and CD3+ infiltrat­ing cells. We determined the capability to infiltrate malignant structures accord­ing to differences in infiltration of benign and malignant prostate structures.

Results: Biometric analysis confirmed that the number of CD204+ macrophages in the malignant structure was significantly higher than in the benign prostatic hyperplasia regardless of the fusion pattern. Increased infiltration by CD3+ cells was only detected in malignant structures of the prostate in a group with normal signal pattern and in a group with TMPRSS2-ERG fusion. Expression of ERG positively correlated with CD204+ and CD3+ cells infiltration of malignant structures only in cases where the TMPRSS2-ERG fusion was found. In the group with a break in the TMPRSS2 gene, a positive correlation was only found between ERG expression and CD204+ macrophages infiltration. In cases with a normal signal pattern, no correlation was found. In the group with TMPRSS2-ERG fusion we observed significantly more cases with a good capability of CD204+ cells to infiltrate malignant structures, unlike the group with a normal signal pattern, where there were more cases with the weak reactivity of CD204 + cells to infiltrate the malignant structures. The same was observed for CD3+ cells. CD204+ macrophages and CD3+ T-lymphocytes in the group with TMPRSS2-ERG gene fusion, infiltrated the malignant prostate structures more intensely, but their effect on malignant transformation may be different.

Conclusions:

The association between the presence of the TMPRSS2-ERG fusion and the different capability of inflammatory cells to infiltrate malignant structures has not been reported so far. The results confirm the important role of the activated ERG gene, due to TMPRSS2-ERG fusion, in the development of inflammation of the prostate as well as the effect of inflammatory cells on the course of neoplastic process. This leads to considerations about introduc­ing immunomodulatory modalities into prostate cancer therapeutic protocols.

Key words:

prostate cancer –TMPRSS2-ERG gene fusion – ERG – immune response – CD204+ macrophages – CD3+ T-lymphocytes

Introduction

Chronic inflammation is an important cause of tumorigenesis in various types of malignancy, includ­ing prostate cancer (CaP) [1,2]. Inflammation may influence the pathogenesis of CaP by modify­ing the tumor microenvironment, remodell­ing the extracellular matrix and initiat­ing epithelial-mesenchymal transition [3]. Inflammatory stress causes repeated genomic damage lead­ing to transformation, vascularization, apoptosis and DNA mutations. Inflammatory cells secrete a number of cytokines that activate other stromal elements, promote tumor growth and initiate formation of metastasis. Inflammation correlates with an increased risk of develop­ing proliferative inflammatory atrophy, and can mask prostatic intraepithelial neoplasia (PIN) or incipient carcinoma in benign prostatic hyperplasia (BPH), which may lead to misinterpretation of the examined bio­psy [4,5].

An important component of the tu­mor microenvironment are tumor-associated macrophages (TAMs) and tumor infiltrat­ing dendritic cells that can induce immunosuppression and thus promote, in co-operation with in­filtrat­ing lymphocytes, tumor progres­sion [6]. Macrophages are a major component of tumour infiltrat­ing im­mune cells, which can promote cancer initiation, progression and metastasis. TAMs infiltration has been shown to correlate with poor prognosis in cancers of breast, cervix, and bladder. However, it correlates probably with better prognosis for non-small cell lung cancer and colorectal cancer, which suggests distinct mechanisms in different tumor types and/or different tissue environments. Many studies have been carried out to look into macro­phage associated markers in CaP samples us­ing various cohort sizes and end points. However, the results remain controversial [7].

The ERG oncoprotein is known to be able to induce PIN, and in CaP cells, where it is expressed at 20–100× higher concentrations than in benign tissues, it stimulates prostaglandin mediated signalling. Androgen dependent in­duction of the ERG expression results from TMPRSS2-ERG gene fusion [8–10]. There is a possible link between the ability of the fusion gene to affect pros­taglandin levels or generally, inflam­mation and the function of the pathway affected by cyclooxygenase-2, an enzyme that controls prostaglandin synthesis. Overexpression of ERG is also inversely proportional to the expression of 15-hydroxyl-prostaglandin dehydrogenase, an enzyme involved in prostaglandin degradation. The ability of prostaglandins to induce CaP growth, regulate expression of the urokinase-type plasminogen activator and con­tribute to tumor cell invasiveness has been demonstrated [8,9].

In this study, we focused on deter­mination a correlation between CD204+ macrophages and CD3+ T-lymphocytes infiltration in malignant, pre-malignant and benign prostate structures, ex­pression of the ERG oncoprotein and the occurrence of the TMPRSS2-ERG gene fusion, respectively. A correlation could suggest the immunomodulatory role of ERG in CaP.

Materials and methods

Analysed cases were randomly selec­ted from the tissue bank of the Depart­ment of Clinical and Molecular Patho­logy, Palacky University and University Hospital, Olomouc. They included archival formalin-fixed, paraffin-embed­-ded tissue samples from 100 patients who had undergone radical prostatec­tomy between 2004–2011 for prostate adenocarcinoma in grades T1–T4, N0–N1, M0. Patients had not received hormonal or radiation ther­apy before the radical prostatectomy or adjuvant ther­apy before recurrence. The study was approved by the institutional ethics committee board. The morphological criteria for “normal”, “BPH”, “PIN” and “malignant prostatic epithelium” con­formed to previously published defi­nitions [11]. Sample sections were used for fluorescence in situ hybridi­zation (FISH) analysis and for immuno­histochemical detection of CD3, CD204 and ERG. ERG expression was evaluated us­ing a commercial rabbit anti-ERG monoclonal antibody (clone EPR3864, Epitomics, Burlingame, California, USA), CD3 expression us­ing a rabbit anti-CD3 polyclonal anti­body (cat. no. AO452, Dako, Agilent Technologies, Santa Clara, California, USA) and CD204 expression us­ing rabbit anti-CD-204 polyclonal antibody (cat. no. HPA000272-100VL, Sigma-Aldrich, St. Louis, Missouri, USA). The protocol for immunohistochemistry was as follows – slides were deparaf­finized, exposed to heat-induced anti­gen re­trieval in autoclave for 5 min at 121 °C and pH 7.8 (ERG) and blocked with preantibody solution (10 min). The antibody against ERG was applied in a dilution 1 : 400 for 60 min at room temperature. Primary antibodies were visualized us­ing the DAKO EnVision Kit (Dako, Agilent Technologies, Santa Clara, California, USA) accord­ing to producer recommendations and 3.3’-diami­-nobenzidine (20 min, Sigma Fast 3.3’-diaminobenzidine tablets). Sections were then counterstained with hemato­xy­lin, dehydrated, cleared, mounted, and covered. Only nuclear stain­ing of ERG was scored us­ing the H-score system obtained by multiply­ing the intensity of the stain (0 – no staining; 1 – weak staining; 2 – moderate staining; 3 – intense staining) by the percentage (0–100) of cells show­ing that stain­ing intensity (H-score range, 0–300). For negative controls, the primary anti­bodies were omitted. As positive control for CD3 and CD204 expression, the positivities of tissue lymphocytes and macrophages were used.

We had previously performed FISH for determination of the TMPRSS2-ERG gene fusion in this cohort of patients [12]. Accord­ing to observed signal patterns, individual cases were divided into 3 groups, see below. The assessment was performed as follows – FISH analysis was carried out us­ing Poseidon TMPRSS2--ERG (21q22) Del, Break, TC Probe (Kreatech Dia­gnostics, Amsterdam, The Netherlands), which is optimised to detect deletion between TMPRSS2 and ERG associated with the TMPRSS2-ERG fusion in a triple-color deletion assay. It also detects translocations involv­ing the TMPRSS2 region. Formalin-fixed, paraffin-embedded tissue sections were used for interphase FISH. Deparaffinized tissue was treated with 0.2 M HCl (hydrochloric acid) for 20 min, NaSCN (sodium sulphocyanide) for 30 min at 80 °C and digested with pepsin (Sigma-Aldrich, USA) for 70 min. The tissues and FISH probe were co-denatured for 5 min at 80 °C and hybridized overnight at 37 °C in a humid chamber (StatSpin ThermoBrite, IRIS, Massachusetts, USA). FISH interpretation was carried out by a molecular cytogeneticist and a patho­logist, both experienced in analys­ing interphase FISH experiments. Hematoxylin and eosin sections were available for side-by-side comparison with the FISH image to localise tumor cells. Paired benign prostatic epithelium was also evaluated as a negative control. Expected signal patterns accord­ing to instructions of the TMPRSS2-ERG probe manual – a nucleus with the TMPRSS2--ERG fusion (group 1 –TMPRSS2-ERG fusion) demonstrates loss of green signal leav­ing a red/blue signal at 21q22. A nucleus with a split of the probe in case a translocation at 21q22 (group 2 – break in TMPRSS2) resulted in a break of the fusion signal, observed as a single red and green/blue signal pattern at the derivative chromosomes, and a nucleus without TMPRSS2-ERG rearrangement (group 3 – normal signal pattern) demonstrated 2 pairs of juxtaposed green, red and blue signals. The samples were analysed under a 100x oil immersion objective us­ing an Olympus BX-51 fluorescence microscope (Olym­pus, Center Valley, Pennsylvania) equip­ped with appropriate filters, a CCD (charge-coupled device) camera and captured by ISIS software (MetaSystems, Altlussheim, Germany).

Evaluation of the number of CD3+ and CD204+ cells was performed by the method of determin­ing their average number in the field of view at the greatest magnification (high power magnification). Characteristic immunohistochemical stain­ing patterns are shown in Fig. 1–4.

1. CD204+ macrophages inside ductus crossing structures of prostate cancer.
CD204+ macrophages inside ductus crossing structures of prostate cancer.

2. CD204+ macrophages infi ltrating structures of prostatic intraepithelial neoplasia.
CD204+ macrophages infi ltrating structures of prostatic intraepithelial neoplasia.

3. CD204+ macrophages inside prostate cancer structures.
CD204+ macrophages inside prostate cancer structures.

4. CD3+ lymphocytes infi ltrating prostate cancer structures.
CD3+ lymphocytes infi ltrating prostate cancer structures.

We divided the patients into sub­groups accord­ing to the degree of infiltration of their CD204+ macrophages and CD3+ lymphocytes and accord­ing to difference of infiltration in benign, premalignant and malignant prostate structures. We interpreted this differ­ence as the capability of immuno­competent cells to reflect the cancer develop­ment. Based on the capability of CD204+ and CD3+ cells to infiltrate the tumor structures, cells was divided as follows:

  • CD204+ infiltration: W – weak without significant changes in the number of positive cells (in comparison with BPH have CaP or PIN increase max. of 5 or decrease – weak reactivity), G – good (increase in CaP or PIN by more than 5 – good reactivity);
  • CD3+ infiltration: W – weak without substantial increase in positive cell count (in comparison with BPH have CaP or PIN increase by a max. of 5 – weak reactivity), G – good (increase in CaP or PIN by more than 5 – good reactivity).

In addition, we performed an evalua­-tion of the intensity of inflammation by the method evaluat­ing the number of „hot spots“ [13].

Statistical analysis

The data were analyzed us­ing SPSS 15.0 software package (SPSS Inc., Chicago, Illinois, USA), and a two-tailed P value of less than 0.05 was considered statistically significant. In the case that the Shapiro-Wilk test of normality revealed non-normal distribution, the
nonparametric Kruskal-Wallis and Mann-
-Whitney U tests with Bonferroni cor­rection were used. The relation of age to other tested parameters was performed by ANOVA. The multiple correlations were assessed us­ing the Spearman coefficient of determination, and categorial data were tested us­ing the Χ2 test and/or in the case of low numbers, the Fisher exact 
test.

Results

Infiltration of prostate lesions by CD204+ macrophages

The number of CD204 + macrophage infiltration is increas­ing in direction from BPH through PIN to CaP, regardless of fusion status (group 1 –TMPRSS2-ERG fusion; group 2 – break in TMPRSS2; group 3 – normal signal pattern). The number of CD204+ inflammatory cells was highest in group 1 and gradually declined downward in group 2 and the lowest number was observed in group 3. A gradual decrease in the level of CD204+ cells infiltration in direction from group 1 to group 3 is evident primarily in CaP (14.1 – 10.0 – 5.5). Significant decrease is also visible in PIN lesions, however, there is no observed gradual decline (e.g. PIN 3.93 – 4.6 – 1.9). This decrease is not observed in BPH (Graph 1A–C). The Kruskal-Wallis test showed that groups 1 and 3 significantly differed in the number of infiltrat­ing CD204+ cells in PIN (p = 0.005) and in CaP (p = 0.0002). Groups 1 and 2 in CaP had a significantly higher CD204+ macrophages infiltra­tion than group 3 with the P values, p ≤ 0.001 and p ≤ 0.015, respectively (Graph 2).

1. A–C. Kruskal-Wallis tests have shown that groups 1 and 3 differ in parameters CD204 PIN (p = 0.005), CD204 CaP (p = 0.0002) and CD3 BPH (p < 0.0001). BPH – benign prostatic hyperplasia, PIN – prostatic intraepithelial neoplasia, CaP – prostate cancer
A–C. Kruskal-Wallis tests have shown that groups 1 and 3 differ in parameters
CD204 PIN (p = 0.005), CD204 CaP (p = 0.0002) and CD3 BPH (p < 0.0001).
BPH – benign prostatic hyperplasia, PIN – prostatic intraepithelial neoplasia, CaP – prostate
cancer

2. Group 1 had, in CaP, a significantly higher CD204+ macrophages infi ltration than group 3 (p ≤ 0.001) and the group 2 had also significantly higher infiltration than group 3 (p ≤ 0.015).
CaP – prostate cancer
Group 1 had, in CaP, a significantly higher CD204+ macrophages infi ltration
than group 3 (p ≤ 0.001) and the
group 2 had also significantly higher infiltration than group 3 (p ≤ 0.015).<br>
CaP – prostate cancer

Infiltration of prostate lesions by CD3+ T-lymphocytes

The increas­ing number of CD3+ T-lymphocytes in a direction from BPH through PIN to CaP, is only visible in group 3 (normal signal pattern) and less clearly for group 1. The opposite trend was observed in group 2 (BPH 21.3; PIN 20.5; CaP 18.3). Also the absolute values of the number of CD3+ cells in the CaP structures, are not significantly different (Graph 1a, 1b, 1c). The Kruskal-Wallis test showed that groups 1 and 3 significantly differ in the number of infiltrated CD3+ cells in BPH (p < 0.0001).

Association between capability of CD204+ and CD3+ cells to reflect malignant transformation of prostate and gene rearrangement

We found that groups 1, 2 and 3 sta­tistically significantly differed in the distribution of cases with CD204+ cells reactivity (Fisher exact test p < 0.0001). Post hoc tests with Bonferroni cor­rec­tion show that groups 1 and 3 sig­nificantly differ (p < 0.0001). There were significantly more cases with good reactivity of CD204+ cells in group 1 (TMPRSS2-ERG fusion) compared to group 3 (normal signal pattern) where a weak reactivity of CD204+ cells predominated. Groups 1, 2 and 3 also differed statistically significantly in the distribution of CD3+ cells reactivity (Fisher exact test p < 0.0001). Post hoc tests with Bonferroni correction showed that groups 1 and 3 (p = 0.004) and groups 2 and 3 (p < 0.0001) were significantly different. There was no significant difference between groups 1 and 2 (p = 0.748). There were sig­ni­ficantly more cases with good reactivity of CD3+ cells in group 1 and significantly more cases with weak reactivity of CD3+ cells in group 3.

Relationship between infiltration of CD204+ and CD3+ cells, their capability to reflect malignant transformation, inflammation and ERG expression

Positive correlations between higher expression of ERG and higher infiltration of CD204+ macrophages (p = 0.0001) and CD3+ T-lymphocytes (p = 0.007) in the tumor microenvironment was observed only in cases with detected TMPRSS2-ERG gene fusion (group 1). In cases with rearrangement in TMPRSS2 gene, a positive correlation was found only between ERG expression and CD204+ macrophage infiltration (p = 0.002). No correlation was found in group 3 (normal signal pattern). There was a significantly higher number of inflammatory hot spots in cases with good reactivity of CD204+ cells compared with cases with weak reactivity of CD204+ cells (p = 0.017) in the CaP (Graph 3).

3. Cases with good reactivity of CD204+ cells (G) have in prostate cancer a significantly higher number of infl ammatory hot spots than cases with weak reactivity of CD204+ cells (W) (p = 0.017).
CaP – prostate cancer
Cases with good reactivity of
CD204+ cells (G) have in prostate cancer
a significantly higher number of infl ammatory
hot spots than cases with weak
reactivity of CD204+ cells (W) (p = 0.017).<br>
CaP – prostate cancer

Cases with good reactivity of CD204+cells as well as CD3+ cells had signifi­cantly higher ERG expression in CaP than cases with weak reactivity of CD204+ cells or CD3+ cells (p = 0.047, p = 0.003) (Graph 4, 5).

4. Using the Mann-Whitney U test, a higher ERG protein expression was shown in the cases with good reactivity of CD204+ cells (G) than in the cases with weak reactivity of CD204+ cells (W) (p = 0.047).
CaP – prostate cancer, H-index – histoscore
Using the Mann-Whitney U test,
a higher ERG protein expression was
shown in the cases with good reactivity of
CD204+ cells (G) than in the cases with weak
reactivity of CD204+ cells (W) (p = 0.047).<br>
CaP – prostate cancer, H-index – histoscore

5. Using the Mann-Whitney U test, a higher ERG protein expression was shown in the cases with good reactivity of CD3+ cells (G) than in the cases with weak reactivity of CD3+ cells (W) (p = = 0.003).
CaP – prostate cancer, H-index – histoscore
Using the Mann-Whitney U test,
a higher ERG protein expression was
shown in the cases with good reactivity of
CD3+ cells (G) than in the cases with weak
reactivity of CD3+ cells (W) (p = = 0.003).<br>
CaP – prostate cancer, H-index – histoscore

Discussion

Epidemiological studies of CaP show significant associations between in­flammation and cancer. Cellular stress induced by inflammation causes re­peated genomic damage lead­ing to cellular transformation, vascularization and DNA mutation. Bacterial infection results in prostatic tissue infiltration with neutrophilic granulocytes, macrophages and lymphocytes. This results in the production of reactive oxygen, nitrogen radicals and various cytokines that change the tissue microenvironment, cause irreversible DNA damage and malig­nant transformation [10]. Inflam­matory cells also produce and release a variety of enzymes, cytokines and chemokines that promote the growth and spread of tumor cells. On the other hand, inflammatory cells also participate in the immune response and some types of cells are associated with sig­nificant tumor suppression and anti­tumorigenesis. It is not yet clear, what type of the cells have carcinogenic or anti-tumor impact. Fujii et al. evaluated the significance of inflammatory in­filtrates, which contain cells express­ing CD3, CD4, CD8, CD20, CD79alpha, CD68 CD204 CD163 antigens and represent a broad spectrum of T-lymphocytes, B-lymphocytes and macrophages in prostate carcinogenesis [2]. They found that in general, the number of inflam­matory cells in the infiltrate was highest in BPH and gradually decreased in PIN and CaP. Their findings were supported by Engelhardt et al [1]. Theyer et al. indicated that T-lymphocytes (70%) prevail in prostate infiltrate, followed by B-lymphocytes (15%) and macrophages (15%) [14]. However, Fujii et al. found a significantly higher proportion of B-lymphocytes (59%) in benign prostate structures, which significantly decreased in PIN and CaP (29–31%) [2]. They found no significant differences in the presence of CD3+, CD4+ and CD8+ (T-lymphocytes) cells for BPH, PIN and CaP. In this respect, our results concern­ing CD3+ T-lymphocytes are consistent with these findings, because differences, which we found between these structures, were not significant. A certain propensity to increased infiltration in malignant structures was observed only in the group with a normal signal pattern. The highest number of infiltrat­ing CD3+ cells was detected in CaP and gradually declined in PIN and was the lowest in BPH. It is unclear whether these results were affected by the “bug of small numbers” or whether they indicate that the capability of CD3+ T-lymphocytes to infiltrate malignantly transformed lesions occurs through a mechanism independent of the presence of the fusion gene. CD3+ marker is expressed in all mature T-cells, which include different subtypes of lymphocytes with different functions. Therefore, it is not possible to determine what qualitative changes in the composition of T-cell lymphocyte subpopulations occur in the tumor or whether these changes have a supportive or inhibitory effect on the tumor.

Some papers highlighted the impor­tance of macrophages produc­ing chemotactic protein-1 (MCP-1) and emphasized that tumor infiltration by these TAMs correlates with a poor prognosis for some types of human malignancies. These macrophages express an antigen known as CD204. Wang et al. described an increase in the number of CD204+ macrophages in premalignant and especially malig­nant regions of analyzed tissue samples compared to BPH [15]. The authors concluded that CD204+ macrophages play a role in tumor development. However, it is not clear whether they are involved in promotion or inhibition of tumor progression. Macrophages can be classified accord­ing to their function as tumor-suppressive (M1 macrophages) and/or tumor-supportive (M2 macrophages). M2 macrophages are characterized by high production of IL-4 and IL-10 and low production of IL-12. They play important roles in tumorigenesis, angiogenesis, matrix remodelling, and metastasing. M2 ma­c­­rophages express a “macrophage scavenger receptor A” (MSR1, also known as CD204, SR-A – marker of alternatively activated macrophages) or a protein CD163, a member of the “scavenger receptor cysteine-rich domain” family [2,7].

Fujii et al. also reported that CD204+ cells were more abundant in PIN and adenocarcinoma than in benign glands [2]. In contrast, infiltration of CD68+ macrophages was high in BPH but reduced in PIN and adenocarcinoma. This disconcordance could be explained by the fact that not all M2 macrophages have to be positive for the CD68+ marker. From these results, the authors suggested that the presence of CD204+ macrophages is an indicator of tumor progression. Recent studies have also reported the presence of CD68+ or CD204+ macrophages in borderline and malignant tumors, includ­ing CaP, glioma and pancreatic cancer [16,17]. Our results relat­ing to CD204+ macrophages in CaP strongly support their tumor-supportive role. In the present study, we confirm an increased count of CD204+ macrophages in malignant structures. The number of infiltrat­ing CD204+ macrophages increased from BPH, via PIN to CaP, regardless of the TMPRSS2--ERG gene fusion status. However, the grade of infiltrat­ing CD204+ macrophages differed between groups with different fusion status (group 1 –TMPRSS2-ERG fusion; group 2 – break in TMPRSS2; group 3 – normal signal pattern). In structures of CaP we found the most significant difference between TMPRSS2-ERG gene fusion status and grade of infiltration. The largest number of CD204+ infiltrat­ing cells was detected in CaP with the TMPRSS2-ERG gene fusion, and the lowest number of these infiltrat­ing cells was found in the CaP without this gene rearrangement (group 3 – normal signal pattern). It is known that ERG protein in CaP cells affects signall­ing mediated by prostaglandin positively and thus contributes to tumor progression. It appears that the existence of TMPRSS2-ERG fusion gene, or any other chromosome rearrangement in the TMPRSS2 gene, may stimulate the capability of CD204+ macrophages to infiltrate tumors. Our results confirm the important role of the ERG oncoprotein, which is overexpressed in the prostate due to the TMPRSS2-ERG fusion gene leads to modulation of inflammation in the prostate.

We report not only an association between the grade of CD204+ and CD3+ cells infiltration in tumor structures with the presence of the TMPRSS2-ERG gene fusion, but also with the expression of the ERG protein. The association between the TMPRSS2-ERG gene fusion and the different ability of inflammatory cells to infiltrate malignant structures has not been reported to date. This higher responsiveness of inflammatory cells for infiltrat­ing malignant structures may not be a feature of an antitumor-based process that is associated with a better prognosis, but on the contrary, it may be an expression of inhibition of the immune system and induction of the immune tolerance. Nevertheless, a more accurate insight into the role of these infiltrat­ing cells in prostate carcinogenesis and cancer progression is 
needed.

This work was supported in part by grant LF_2018_001 and grants NPS I LO1304 and DRO (UP, 61989592) from the Czech Ministry of Education.

The authors would like to thank dr. Katerina Langova for statistical evaluation and Ing. Ivo Uberall for photographic documentation.

The authors declare they have no potential conflicts of interest concerning drugs, pro­ducts, orservices used in the study.

The Editorial Board declares that the manu­script met the ICMJE recommendation for biomedical papers.

Submitted: 5. 8. 2018

Accepted: 25. 10. 2018

prof. MUDr. Zdeněk Kolář, CSc.

Department of Clinical and Molecular Pathology

Faculty of Medicine

Palacky University in Olomouc

Hnevotinska 3

775 15 Olomouc

e-mail: zdenek.kolar@upol.cz


Sources

1. Engelhardt PF, Brustmann H, Seklehner S et al. Chronic asymp­tomatic inflam­mation of the prostate type IV and carcinoma of the prostate: is there a cor­relation? Scand J Urol 2013; 47(3): 230–235. doi: 10.3109/ 00365599.2012.733961.

2. Fujii T, Shimada K, Asai O et al. Im­munohistochemical analysis of inflam­matory cel­ls in benign and pre­cancerous lesions and carcinoma of the prostate. Pathobio­logy 2013; 80(3):119–126. doi: 10.1159/000342396.

3. Stark T, Livas L, Kyprianou N. Inflam­mation in prostate cancer progres­sion and therapeutic targeting. Trans Androl Urol 2015; 4(4): 455–463. doi: 10.3978/j.is­sn.2223-4683.2015.04.12.

4. Nakai Y, Nonomura N. Inflam­mation and prostate carcinogenesis. Int J Urol 2013; 20(2): 150–160. doi: 10.1111/j.1442-2042.2012.03101.x.

5. Ørsted DD, Bojesen SE. The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol 2013; 10(1): 49–54. doi: 10.1038/nrurol.2012.192.

6. Hanada T, Nakagawa M, Emoto A et al. Prognostic value of tumor-as­sociated macrophage count in human bladder cancer. Int J Urol 2000; 7(7): 263–269. doi: 10.1046/j.1442-2042.2000.00190.x.

7. Cao J, Liu J, Xu R et al. Prognostic role of tumour-as­sociated macrophages and macrophage scavenger receptor 1 in prostate cancer: a systematic review and mate-analysis. Oncotarget 2017; 8(47): 83261–83269. doi: 10.18632/oncotarget.18743.

8. Martin SK, Kyprianou N. Gene fusions find an ERG-way to tumor inflam­mation. Cancer Biol Ther 2011; 11(4): 418–420. doi: 10.4161/cbt.11.4.14499.

9. Mohamed AA, Tan SH, Sun C et al. ERG oncogene modulates prostaglandin signal­­ing in prostate cancer cel­ls. Cancer Biol Therap 2011; 11(4): 410–417. doi: 10.4161/cbt.11.4.14180.

10. Bartek J, Hamerlik P, Lukas J. On the origin of prostate fusion oncogenes. Nat Genet 2010; 42(8): 647–648. doi: 10.1038/ng0810-647.

11. Bostwick DG, Cheng L (eds.). Urologic surgical pathology. 2nd ed. Mosby Elsevier 2008.

12. Kolar Z, Burdova A, Jamaspishvili T et al. Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expres­sion to TMPRSS2-ERG fusion status in prostate cancer. Neoplasma 2014; 61(1): 9–16. doi: 10.4149/neo_2014_004.

13. Irani J, Levil­lain P, Goujon JM et al. Inflam­mation in benign prostatic hyperplasia: cor­relation with prostate specific antigen value. J Urol 1997; 157(4): 1301–1303. doi: 10.1016/S0022-5347(01)64957-7.

14. Theyer G, Kramer G, As­smann I et al. Phenotypic characterization of infiltrat­­ing leukocytes in benign prostatic hyperplasia. Lab Invest 1992; 66(1): 96–107.

15. Wang XY, Facciponte J, Chen X et al. Scavenger receptor – A negatively regulates antitumor im­munity. Cancer Res 2007; 67(10): 4996–5002. doi: 10.1158/0008-5472.CAN-06-3138.

16. Komohara Y, Ohnishi K, Kuratsu J et al. Pos­sible involvement of the M2 anti-inflam­matory macrophage phenotype in growth of human gliomas. J Pathol 2008; 216(1): 15–24. doi: 10.1002/path.2370.

17. Kurahara H, Shinchi H, Mataki Y et al. Significance of M2-polarized tumor-as­sociated macrophage in pancreatic cancer. J Surg Res 2011; 167(2): e211–e219. doi: 10.1016/j.js­s.2009.05.026.

Labels
Paediatric clinical oncology Surgery Clinical oncology

Article was published in

Clinical Oncology

Issue 6

2018 Issue 6

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#